UBS maintained a Buy rating for CANSINOBIO despite a net loss of RMB40 million in 1Q26, as the company's revenue of RMB190 million exceeded expectations with a 38.7% year-on-year growth. However, UBS revised its earnings per share forecasts downward for 2026 to 2028 and reduced the target price from HKD59.8 to HKD52.4.
